Background. It is uncertain whether episodic acyclovir will enhance ulcer healing if delivered at primary health care settings, because there is often a delay in treatment initiation.
GUD [3] [4] [5] and as HSV-2 seropositivity, increases the efficiency of human immunodeficiency virus type 1 (HIV-1) acquisition [6] [7] [8] [9] [10] [11] . However, trials evaluating the impact that acyclovir suppressive therapy for herpes had on HIV incidence found no protective effect [12] [13] [14] .
HSV-2 may also increase HIV transmission [15] [16] [17] [18] . HIV RNA has been isolated from herpetic lesions [19] [20] [21] , and herpes recurrences have been associated with transient increases in plasma and genital HIV loads [16] [17] [18] , potentially increasing HIV infectiousness. Although suppressive acyclovir therapy has been studied extensively, there have been no studies evaluating the effect that episodic therapy has on genital HIV-1.
In terms of clinical benefit, current evidence regarding episodic acyclovir treatment for ulcer duration suggest that it is effective when administered early and in the context of first episodes rather than recurrent in-fections [22] [23] [24] [25] [26] . Patients attending primary health care facilities in developing countries are likely to have a delay in symptom recognition and, thus, a delay in treatment initiation. The impact of treatment might be greater in countries with a high prevalence of HIV.
The World Health Organization (WHO) has recommended administering antiherpes therapy as part of syndromic management in settings in which herpes accounts for 130% of GUD [27] . However, few African countries have modified their GUD guidelines and require a base of evidence to advocate for this change in drug therapy for GUD. We conducted a randomized, controlled trial to assess the benefit of adding episodic acyclovir to existing antibiotic-based treatment guidelines for GUD in terms of (1) reducing ulcer duration and (2) reducing HIV-1 ulcer shedding.
METHODS

Study procedures.
This study was an individually randomized, double-blind, placebo-control trial of the addition of acyclovir (400 mg 3 times daily) for 5 days to the routine syndromic management of GUD among men in South Africa. The primary objectives were to evaluate the effect that episodic acyclovir therapy has on the duration of genital ulcers and on the presence and quantity of lesional HIV-1 shedding in HIVpositive men with a herpetic ulcer. A secondary objective was to evaluate the effect that acyclovir has on ulcer healing in the overall study population and in HIV-negative participants. The study was conducted at 3 clinics in Gauteng Province from March 2005 through December 2006. A genital ulcer was defined as a sore on the penis, scrotum, or perianal region. Eligible men were 18-60 years old, had an ulcer present at baseline, were willing to be serologically screened for HSV-2 and HIV, were able to comply with follow-up visits, and accepted therapy by chance. Patients with extensive ulcerations (1500 mm 2 ) and chronic ulcers (11 month's duration) were excluded, because they required immediate therapy. Study clinicians were trained to assess ulcer healing by the naked eye, by assessing type of tissue and wound edges and by measuring ulcer size. If multiple ulcers were present, measurements were taken from the largest one. Ulcer width multiplied by length was adopted as an approximation of the ulcer area. The same clinician conducted repeated measurements to reduce intraobserver variability.
Men provided written informed consent for enrollment and were randomized to receive either acyclovir or placebo. All patients received GUD syndromic therapy (2.4 MU of benzathine penicillin intramuscularly and 500 mg of ciprofloxacin orally). Information on demographics, sexual history and behaviors, ulcer recurrences, and sexually transmitted infection (STI) and HSV-related symptoms was collected by questionnaire. Among the first 85 participants, a pilot study was conducted to compare swabs and lavages for the detection and quantitation of HIV-1 RNA in genital ulcers [28] . There was no difference between lavages and swabs in the ability to detect and quantify HIV-1 RNA. Lavages were chosen as the sampling method for the remainder of the study, on the basis that they allowed collection of a more standardized volume of secretions and were less likely to induce bleeding. Samples were collected in the following order: ulcer lavage for HIV-1 RNA, swab for HSV-2 DNA, and swab for ulcer etiology. Lavages were done by nontraumatic washing with 10 mL of phosphate-buffered saline (PBS) (pH 7.2). The PBS was gently squirted into the ulcer and collected in a sterile cup. Ulcer swabbing was nontraumatic and done by means of a rotational technique. Samples were stored at Ϫ70ЊC until tested. Baseline blood samples were collected for HIV, HSV-2, and syphilis screening and plasma HIV-1 load and CD4 cell testing.
HIV-positive participants were reevaluated on days 2 or 4, 7, 14, and 28. Specimens were collected at each visit to measure HIV-1 and HSV-2 shedding until the ulcer was healed. Blood for plasma HIV loads was collected on days 7, 14, and 28. HIVnegative participants were asked to return for follow-up visits until the ulcer healed, without collection of additional specimens, and also to return on day 28 for a repeat HIV test. During baseline and follow-up visits, the number, size, degree of epithelialization, and intensity of pain of ulcers; adherence to treatment; and adverse events were monitored.
HIV and STI testing. Same-day HIV testing was performed on site with appropriate counseling using 2 rapid HIV tests (Determine [Abbott Laboratories] and Capillus [Trinity Biotech]), in accordance with South African HIV testing guidelines. Discordant results were further tested by 3 enzyme-linked immunosorbent assays (ELISAs) (Bio-Rad, Abbott Murex, and bioMérieux). Serological screening used the Macro-Vue rapid plasma reagin test (Becton Dickinson) and the Treponema pallidum particle-agglutination assay (Fujirebio) for syphilis and a commercial ELISA for HSV-2 (Kalon Biological). Screening of urine for urethritis pathogens was done by polymerase chain reaction (PCR) at enrollment. Ulcer etiology was determined by an in-house multiplex PCR for Treponema pallidum, Haemophilus ducreyi, and HSV, using a method that has been published elsewhere that has a sensitivity of at least 10 copies for each organism when all 3 targets are present [29] . A separate real-time PCR for Chlamydia trachomatis L1-L3 was undertaken (Rotorgene; Corbett Robotics). PCR-based HSV-1/2 typing was subsequently performed. Free STI treatment was provided to those men requiring it on the basis of STI symptoms or positive STI laboratory test results. HIV-positive participants were referred to antiretroviral clinics for evaluation and treatment. However, no newly diagnosed HIV-infected patients started therapy during the study follow-up.
CD4 cell counts were determined using a FACScan flow cytometer (Becton Dickinson Immunocytometry Systems), and plasma HIV-1 loads were determined using an Amplicor HIV-1 monitor test (version 1.5; Roche Diagnostics System). HSV-2 DNA was measured in ulcer swabs by real-time PCR (LightCycler; Roche Diagnostics). The Amplicor HIV-1 Monitor UltraSensitive assay (version 1.5; Roche) was used to quantify HIV-1 RNA levels in ulcer lavage samples. Briefly, 750 mL of ulcer lavage was initially precipitated by centrifugation (23,000 g for 1 h at 5ЊC), and 250 mL of the supernatant was removed and replaced with normal human plasma. The total RNA was extracted from the lavage-plasma mixture in the normal manner. The lower and upper limits of detection were 50 and 100,000 copies/mL, respectively. HSV-2 DNA was measured in ulcer swabs by real-time PCR (LightCycler; Roche Diagnostics). STI/HIV testing was undertaken at the STI Reference Centre and the Specialized Molecular Diagnostic Unit of the National Institute for Communicable Diseases of the National Health Laboratory Service, South Africa. Quality control procedures, type-specific HSV-1/2 testing, and HSV-2 quantitative testing were performed at the STD Laboratory at the US Centers for Disease Control and Prevention (CDC).
Ethics and other approvals. The study was approved by the ethics committees and institutional review boards of the University of the Witwatersrand, the London School of Hygiene and Tropical Medicine, the CDC, and the Gauteng Provincial and City of Johannesburg Health Departments.
Sample size. The sample size of 600 men was based on the expectation that 50% would be HIV positive and that HSV-2 would account for 60% of GUD. It was assumed that 50% of men receiving placebo would have an ulcer on day 7 and that the study would detect a minimum change of 20% in the proportion of men with an ulcer after treatment for a 2-sided Table 1 No. of days with ulcer before baseline, median (IQR) NOTE. Data are no. (%) of participants, unless otherwise indicated. There were no major imbalances between treatment arms among all participants and among HIV-positive participants with a herpetic ulcer for demographic, behavioral, and biological variables. Ulcer etiology was not tested for 2 individuals. CI, confidence interval; IQR, interquartile range; STI, sexually transmitted infection. a For duration of ulcer before baseline, among all participants. P p .08 b There were 3 individuals in the placebo arm who had HSV in the ulcer by polymerase chain reaction but for whom we did not have HSV typing information (these are included in the HSV-2 group in the table). Of the participants with mixed etiology for Treponema pallidum and herpes, there were 5 with T. pallidum, HSV-1, and HSV-2; 3 with T. pallidum and HSV-1; and 2 with T. pallidum and HSV-2.
. Description of Study Participants by Baseline Characteristics among All Participants Enrolled in the Trial and among Human Immunodeficiency Virus (HIV)-Positive Participants with a Herpes Simplex Virus (HSV) Ulcer
alternative at the .05 significance level with 80% power. We hypothesized a minimum of 0.5 log 10 reduction in lesional HIV-1 shedding among men receiving acyclovir [30] .
Statistical analysis. The primary outcomes for the study were (1) proportion healed as assessed by study clinician on day 7; (2) time to healing assessed by study clinician and patient self-reports (median time to healing); (3) proportion shedding HIV-1 from ulcers on day 7; and (4) mean HIV-1 shedding from ulcers on day 7. An intent-to-treat strategy was used in data analysis. Continuous variables were presented as medians with ranges or as means with standard deviations. For positively skewed continuous data, a logarithmic base 10 transformation was applied. For continuous variables, treatment arms were compared using the Wilcoxon rank-sum test. For categorical variables, a x 2 test was used. HIV-1 lesional shedding values recorded at the limit of detection were treated as left-censored at 50 copies/mL. Maximum likelihood estimation (MLE) methods were used to estimate the mean and compare the 2 ran- .473
NOTE.
The proportion healed indicates the participants whose ulcers were healed at any time between baseline and day 7. The relative risk (RR) was adjusted for study site by means of modified Poisson regression, and the hazard ratio (HR) was adjusted for study site and baseline self-reported duration of ulcer by means of the Cox proportional hazards model. Initial HSV-2 is defined as HSV-2 seronegative with an HSV-2 ulcer. CI, confidence interval.
domized treatment arms [31] [32] [33] , assuming a normal distribution of log 10 HIV-1 shedding. Tobit regression [34] was used to evaluate the adjusted effect of treatment on the mean quantity of HIV RNA. In addition, lesional HIV-1 shedding was categorized as a binary outcome, and modified Poisson regression was used to estimate adjusted relative risks (aRRs) and 95% confidence intervals (CIs). Interaction terms between treatment and CD4 cell count and between treatment and time of presentation were evaluated.
If the person was missing the day 7 visit, the healing status on day 2 or 4 was used. If the ulcer was reported as healed on either day 2 or 4, then it was recorded as healed on day 7. Otherwise, it was treated as missing. We assessed the sensitivity of this approach by comparing the results to that of simply using only the data available on day 7, and the difference in the estimates was negligible. Time to healing was assessed by identifying the first follow-up visit at which the clinician assessed either a 90% reduction or more in the ulcer area, compared with baseline, or complete reepithelialization. Patient reports of ulcer duration were also used to calculate median duration. A Kaplan-Meier survival curve was used to estimate the median, and the log-rank test was used to test whether the survival function of the 2 study arms was different. To control for study site and baseline imbalances, the Wald test from a proportional hazards model was used to test whether the survival experiences between study arms were significantly different.
Analyses were also performed on the following predefined subgroups: HIV positive with a herpetic ulcer (both HSV-1 and HSV-2), HIV negative with a herpetic ulcer, and HSV-2 seronegative with an HSV-2 ulcer (initial episode). We also planned to evaluate differences in treatment effect by time of presen-tation (number of days since the genital ulcers were first noticed by the patient) and CD4 cell counts. Statistical analyses were performed using SAS software (version 9.1; SAS Institute).
RESULTS
A total of 1559 men were screened and, of 635 eligible participants, 615 were randomized, 309 to acyclovir and 306 to placebo ( Figure 1) . The age and residence of the men who were not enrolled were similar to those of the study participants. In each arm, 28 participants were lost to follow-up. There was no difference by treatment arm or baseline variables between those lost to follow-up and those who participated through day 28 among all participants and among HIV-positive participants.
Of the enrolled men, 387 (63.0%) were HIV seropositive, and 434 (70.6%) were HSV-2 seropositive; 451 (73.6%) of the ulcers were herpetic. There were 295 HIV-positive men with a herpetic ulcer (146 receiving acyclovir and 149 receiving placebo). Most herpetic ulcers were caused by HSV-2, although 16 participants were HSV-1 positive (14 of 16 were dually infected with HSV-2) ( Table 1) .
Participants' median age was 29 years (interquartile range [IQR], 25-35 years). There were no major imbalances between treatment arms among all participants and among HIV-positive participants with a herpetic ulcer (Table 1) . Among HIV-positive participants, the median baseline CD4 cell count was 282 cells/mL (IQR, 165-418 cells/mL), the median plasma viral load was 87,200 copies/mL (IQR, 25,700-209,000 copies/mL), and 45.4% ( ) had detectable HIV-1 in ulcers. The mean n p 173 log 10 HIV-1 load in lesions was 1.58 log 10 copies/mL (95% CI, 1.36-1.79 log 10 copies/mL). Nine men were receiving antiretroviral drugs. herpetic ulcer (B) . The proportion of patients who received acyclovir whose lesions were not healed on the day indicated is represented by an interrupted line, and the proportion among those who received placebo is represented by a solid line. Time to healing among those who healed was estimated using the self-reported number of days since the ulcer was healed reported at the visit when it was noted as healed. Participants who did not heal were censored at their last visit. Differences in hazard ratios were significant for the overall group ( ) (A) and for the group of HIV-positive participants with herpetic ulcers ( ) (B). The data below the figures present the P p .01 P p .001 individuals at risk and healed for each interval. The notation [x, y) means and reflects the right continuity of the Kaplan-Meier curve. Adherence to 100% of prescribed tablets measured by selfreport and by pill counts was 88.4% and 85.1% (acyclovir arm) and 90.0% and 89.0% (placebo arm), respectively. Among those with !100% adherence, the median number of tablets taken was 14 (IQR, [12] [13] [14] . The prevalence of reported adverse events did not differ by treatment arm. There were 3 AIDS-related serious adverse events (2 hospitalizations and 1 death), but none of these were related to the study drug.
Impact of acyclovir on ulcer healing. Ulcers healed faster in participants receiving acyclovir. Among all participants, 64.4% ( ) receiving acyclovir had a healed ulcer on day n p 186 7, compared with 49.6% ( ) receiving placebo (aRR, 1.3 n p 140 [95% CI, 1.1-1.5]). Among the HIV-positive participants with a herpetic ulcer, the proportions were 60.6% ( ) and n p 80 42.4% ( ), respectively (aRR, 1.4 [95% CI, 1.1-1.8]). A n p 59 difference by treatment arm was also seen on day 14 (aRR, 1.1 [95% CI, 1.0-1.2]) but not on day 28 (aRR, 1.0 [95% CI, 0.9-1.1]). Acyclovir treatment did not enhance HSV ulcer healing among HIV-negative participants ( Table 2 ).
There were 133 initial episodes of genital herpes; 54 (40.6%) were HIV positive, and healing information was available for 123 (92%). Acyclovir resulted in improved healing among this group; on the day 7 visit, 64.6% in the acyclovir arm had a healed ulcer, compared with 46.6% in the placebo arm (aRR, 1.5 [95% CI, 1.1-2.1]).
The effect of acyclovir was greater among HIV-positive men with a CD4 cell count 1200 cells/mL (aRR, 1.5 [95% CI, 1.2-2.0]) than those with a count р200 cells/mL (aRR, 1.3 [95% CI, 0.9-1.8]). However, the interaction between treatment and CD4 cell count was not statistically significant ( ). P p . 41 There was evidence that acyclovir provided greater benefit to those men who presented early for treatment. Among men who had an ulcer for 5 days or fewer before baseline, 70.6% ( ) receiving acyclovir had a healed ulcer on day 7, comn p 48 pared with 47.1% ( ) receiving placebo (aRR, 1.5 [95% n p 33 CI, 1.1-2.0]). Among men who presented later, the difference was 49.2% ( ) and 36.8% ( ), respectively (aRR, n p 30 n p 25 1.3 [95% CI, 0.9-1.9]). However, the interaction between treatment and time of presentation was not significant ( ). P p .66 Time to healing was shorter in the acyclovir group than the placebo group among all trial participants (median, 6 and 7 days, respectively; ) ( Figure 2) , among HIV-positive P p .006 participants with a herpetic ulcer (median, 6 and 9 days, respectively;
( Figure 2 ), and among those with initial P ! .001 herpes episodes (median, 6 and 8 days, respectively) (P p ). These associations were adjusted for study site and du-.032 ration of ulcers before baseline ( Table 2) .
Impact of treatment on HIV load in genital ulcers. Among HIV-positive participants with a herpetic ulcer, fewer men receiving acyclovir had detectable lesional HIV-1 RNA on days 7 (23.9% vs 37.1%; aRR, 0.7 [95% CI, 0.4-1.0];
) and P p .049 14 (14.7% vs 37.5%; aRR, 0.4 [95% CI, 0.2-0.9];
). P p .024 Secondary to the healing process, there were only 36 ulcer specimens available for testing from the day 28 visit; no difference was observed between study arms (Figure 3) .
Acyclovir treatment was also associated with a reduction in mean lesional HIV-1 RNA level on day 7 (adjusted mean reduction, Ϫ0.82 log 10 copies/mL [95% CI, Ϫ1.45 to Ϫ0.18 log 10 copies/mL) ( Table 3 ). The impact of treatment on HIV shedding on day 7 was greater for men with CD4 cell counts 1200 cells/mL (aRR, 0.4 [95% CI, 0.2-0.9]) than for men with CD4 cell counts р200 cells/mL (aRR, 1.0 [95% CI, 0.6-1.6]). The interaction term for the effect of treatment and CD4 cell count was marginally significant ( ). P p .077 Impact of treatment on HSV-2 shedding from genital ulcers. Acyclovir reduced HSV-2 shedding from ulcers at every visit among HIV-positive participants with a herpetic ulcer-17.6% in the acyclovir group and 63.8% in the placebo group on day 7 (aRR, 0.2 [95% CI, 0.1-0.4]) and 22.6% and 44.9%, respectively, on day 14 (aRR, 0.5 [95% CI, 0.2-1.0;
). The P p .043 quantity of HSV-2 shedding was also reduced ( Table 3) .
Impact of treatment on plasma HIV-1 load. Most HIVpositive participants (97.4%;
) had a detectable plasma n p 369 HIV-1 load at baseline. On day 7, the mean quantity of plasma HIV-1 RNA in the acyclovir group was significantly lower than that in the placebo group among all HIV-positive participants (Ϫ0.19 log 10 copies/mL [95% CI, Ϫ0.37 to Ϫ0.02 log 10 copies/ mL];
) and among HIV-positive participants with a P p .03 
DISCUSSION
The present study has shown that episodic therapy with acyclovir improved ulcer healing by a median of 3 days among HIV-positive men with a herpetic ulcer and reduced HIV-1 shedding from ulcers. A benefit of treatment was also seen among all randomized participants. Although not powered to investigate the treatment effect among the following subgroups, this study observed that patients with higher CD4 cell counts, with initial herpes, and starting therapy earlier responded better to acyclovir.
To date, this is the first placebo-controlled trial to evaluate episodic antiherpes therapy among HIV-infected men. Previous studies evaluating episodic therapy among HIV-positive patients [35, 36] compared 2 different treatment regimens and did not have a placebo arm. Placebo-controlled trials among HIV-negative individuals have found that treatment can improve healing by 1-2 days, but treatment has been effective only if administered at the onset of the recurrence [37] [38] [39] [40] . The absence of a significant effect of treatment among HIVnegative participants in our study was probably due to late initiation of therapy [37] [38] [39] [40] .
We found that episodic treatment reduced both the presence and quantity of HIV-1 shedding from genital ulcers. Although ulcer healing was likely to affect HIV-1 shedding by reducing the ulcer surface area, specimens were collected only among men with unhealed ulcers at follow-up visits and thus provide an estimate of the impact of treatment on HIV-1 shedding as the ulcer heals. We also found modest reductions in plasma HIV load on day 7 among participants taking acyclovir, suggesting that even a short-term reduction if HSV replication could reduce HIV up-regulation locally and systemically. A recent study by McMahon et al [41] provides an alternative explanation for the reductions in HIV loads. Using an HIV infectivity assay, the study found that acyclovir had a direct effect on HIV replication. This may contribute to the reductions in plasma HIV RNA levels seen in coinfected patients receiving suppressive acyclovir therapy [42] [43] [44] and in the present study.
The potential protection of acyclovir suppressive therapy against HIV infection has been evaluated in clinical trials [12] [13] [14] , which found no effect of suppressive therapy with twicedaily acyclovir. An in situ study of sequential biopsy samples of HSV-2 lesions from patients receiving or not receiving antiviral therapy offered a possible explanation for this. The study found that HSV-2 infection results in a profound, persistent localized inflammatory response in the dermis below the healed lesion, consisting of HSV-2-specific CD4 T cells that express CCR5 or CXCR4. Even prolonged antiviral therapy for HSV-2 does not significantly influence this infiltrate [45] . More research should focus on interventions that prevent the acquisition of HSV-2 infection, such as the development of an effective HSV-2 vaccine.
Genital herpes now accounts for the vast majority of sexually acquired genital ulcers in South Africa, whereas syphilis, lymphogranuloma venereum, and chancroid account for only 5%-10% of the total GUD caseload. The study supports current WHO recommendations to include antiherpetic episodic treatment in GUD syndromic management algorithms in countries in which herpes is the predominant GUD etiology [27] . Generic acyclovir is now available, and the cost of a course of treatment has been much reduced, which will assist resource-poor countries with this change in guidelines.
Limitations of the present study include the fact that it was not powered to evaluate the impact of acyclovir among HIVnegative participants. Follow-up was not ideal for days 14 and 28 for the subset of HIV-positive men, but it was better for the overall group. HIV-1 shedding from ulcers was decreased, but the impact of acyclovir on generalized genital tract HIV-1 shedding was not addressed. Because of infrequent visits, the median time to healing was based on self-reported ulcer duration, which could be subject to misreporting. However, analysis based on the clinician's assessment of healing at study visits provided similar results.
In conclusion, the present study has shown that the addition of acyclovir to current GUD antibacterial management results in symptom relief and a reduction in genital HSV-2. The size of the observed reduction in lesional HIV-1 shedding is unlikely to have a significant effect on HIV-1 transmission at the population level. For a more substantial effect on HIV-1 transmission, earlier and more effective interventions to treat and suppress genital herpes are needed. Because the majority of patients with GUD are unlikely to be aware of their HIV serostatus, HIV testing should be strongly recommended to identify patients in need of antiretroviral therapy and enhance HIV prevention through patient-centered counseling. Changes in national treatment guidelines should be accompanied by strategies that will improve early presentation of patients with GUD and increase the ability of clinicians to discuss the link between HSV-2 and HIV.
